Author:
Huang Yanping,Cuan Xiangdan,Yang Xingying,Zhu Weiwei,Zhao Yunli,Jiang Li,Zi Chengting,Wang Xuanjun,Sheng Jun
Subject
Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry
Reference43 articles.
1. Cancer statistics in China and United States, 2022: profiles, trends, and determinants;Xia;Chin. Med. J. (Engl.),2022
2. FOXD1 promotes cell growth and metastasis by activation of vimentin in NSCLC;Li;Cell. Physiol. Biochem.,2018
3. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer;Mu;Clin. Cancer Res.,2005
4. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol.,2010
5. Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)? - the shifting paradigm of therapeutics;Itchins;Transl. Lung Cancer Res.,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献